Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Clofazimine
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Apr/07/2021
Salinomycin
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Apr/07/2021
Silibinin
Potential treatment - theoretical effect Natural product Antiviral Apr/06/2021
CoronaVac
Potential treatment - clinical evidence Experimental Vaccine Apr/06/2021
Arbidol
Recommended by China's NHC Guidelines Used to treat other disease Antiviral Apr/03/2021
Glycyrrhizic acid
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/02/2021
Rutin
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/02/2021
Adjuvanted SARS-CoV-2 Spike protein
Potential treatment - pre-clinical evidence Experimental Vaccine Apr/01/2021
N-[(2S)-1-[[(3S)-1-(benzenesulfonyl)-5-phenylpentan-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
Grazoprevir
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/31/2021
MXB-9
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
MXB-4
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
Topotecan
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/30/2021
rLVS ΔcapB/SCoV2 MN
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/30/2021
Tannic acid
Potential treatment - pre-clinical evidence Natural product Antiviral Mar/30/2021
Omega-3 polyunsaturated fatty acids
Potential treatment - clinical evidence Natural product Unknown Mar/29/2021
FC05
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
P17
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
H014
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
HB27
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021